NEW YORK — TriLink BioTechnologies said Monday that it has signed a distribution agreement for its nucleic acid products with Avantor covering Europe, the Middle East, and Africa. Financial terms of the partnership were not disclosed.
Under the terms of the deal, Avantor will begin offering TriLink's products through its distribution networks in the EMEA region. In addition, the products will be made available through MarketSource, an e-commerce platform run by Avantor subsidiary VWR, in the coming months.
Products covered under the arrangement include TriLink's CleanCap mRNA cap analogs, catalog mRNAs, modified and unmodified nucleotides, and in vitro transcription enzymes.
San Diego-based TriLink, a subsidiary of Maravai LifeSciences, said the partnership is expected to shorten lead times for European customers.
"This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe," TriLink Chief Commercial Officer Becky Buzzeo said in a statement.
Radnor, Pennsylvania-based Avantor has become a distributor for a number of companies in recent months including protein sequencing firm Quantum-Si, digital PCR systems developer Stilla Technologies, and materials analysis company Rigaku Analytical Devices.